|  |
| |
| Schematic representation of the domain structures of MMP-14 (domains are not scaled). |
| |
Description | Matrix metalloproteinases (MMPs) compose one of the metzincins super family also known as zinc endopeptidases. Highly conserved motif of this family contains three histidines that bind zinc ion in the catalytic site of the protein and conserved methionine. Besides the secreted MMPs of the MMP family, six membrane type-MMPs have been identified so far, all with similar domain compositions. The best characterized MT-MMP is MMP-14 or MT1-MMP, which contains seven domains from N-terminus to C-terminus: a signal peptide leading MMP-14 into the secretory pathway; a propeptide domain maintaining MMP in a latent form; a catalytic domain responsible for enzymatic activity; a hinge region maintaining proper conformation; a hemopexin domain required for substrate reorganization; a transmembrane domain anchoring MMP into the plasma membrane; and a cytoplasmic domain required for endocytosis. MT-1, MT2-, MT3- and MT5-MMPs all contain seven similar domains, whereas MT4- and MT6-MMPs lack the transmembrane and cytoplasmic domains. Both MT4- and MT6-MMPs are linked to the cell surface through GPI-anchorage. There is a furin consensus sequence (Arg108-Arg109-Lys110-Arg111) between MMP-14 propeptide and catalytic domains. Furin has been reported to be responsible for MMP-14 activation. However, the activation mechanism of MMP-14 is still under debate. The hemopexin-like domain of MMP-14 is the largest domain, and it provides a suitable flat surface for the protein-protein interactions with the existence of four bladed beta-propeller structures. |
Expression | MMP-14 is widely expressed in human tissues. Its expression has been proven in the adult human intestine, kidney, lung, ovary, placenta, prostate, and spleen. Increase in its expression level has also been observed in the wound healing area. A Mouse embryogenesis study provides evidence for the expression of MMP-14 mainly in the muscle cells, fibroblast, chondrocytes, and neural cells. MMP-14 is upregulated in most human cancers. Both cancer and stromal cells have been reported to be upregulated in tumor tissues. |
Localisation | Plasma Membrane (single-pass type I membrane protein). MMP-14 contains a 24 amino acid hydrophobic motif at the C-terminus which is responsible for plasma membrane localization of MMP-14. |
Function | MMP-14 plays an important role in remodelling of extracellular matrix (ECM) and enhancing cell migration. Besides the role of MMP-14 in these pathophysiological processes, it also plays an important physiological role during development. Studies performed with MMP-14 null mice have shown the importance of its function during embryogenesis as the lack of MMP-14 caused craniofacial dysmorphism, arthritis, osteopenia, dwarfism, fibrosis of soft tissues and premature death. In the adult life, MMP-14 is also required for the wound healing process. All of these functions are related to MMP-14's cleavage or activation of the protein within its substrate profile, which includes proteins in ECM, pro-MMPs, cell-adhesion molecules, cytokines, growth factors and receptors on the cell membrane. Recent studies have also demonstrated the activation of signal transduction pathways via the cytoplasmic tail of MMP-14 important for the invasion process. Functions of MMP-14 can be summarized under the categories of activation of proMMMPs; degradation of ECM; shedding of cell surface molecules; cleavage of cytokines and growth factors; and activation of ERK cascade. I-) Activation of proMMPs and degradation of ECM Pro-MMP2 was the first identified substrate of MMP-14 and the trimolecular complex consisting of MMP-14 and proMMP2-TIMP2 has been investigated very well for many years. TIMP2 (tissue inhibitor of metalloproteinases-2) is actually the inhibitor of the MMPs. However, low concentrations of TIMP-2 aids in the activation of proMMP-2 by MMP-14 within this complex by binding to the catalytic domain of MMP-14 and the C-terminal domain of pro-MMP2. Following the formation of the triplex, a second MMP-14, which is free of TIMP-2, forms a dimer with the pre-existing MMP-14 on the cell membrane and cleaves the latent pro-MMP2 to produce active MMP2. Active MMP-2 can then participate in other events such as the degradation of collagen type-IV, a major protein component of the basement membrane, which is not cleaved by MMP-14 itself. Another substrate of MMP-14 within the MMP family is the pro-MMP-13, which also functions as a collagenase in the surrounding tissue after its activation. Besides activation of MMPs, especially pro-MMP-2, MMP-14 cleaves many proteins in the ECM and changes the composition of the matrix. Type I-Type II-Type III collagen, gelatin, fibronectin, laminin-1 and -5, fibrin and proteoglycans are the major direct targets of MMP-14 in the extracellular environment. Out of these substrates, collagen makes up a significant portion of the ECM and acts as a barrier for migratory cells. Within the collagenases, which includes MMP-1, MMP-2, MMP-8, MMP-13, only MMP-14 can stimulate invasion into collagen by epithelial cells, fibroblasts, and cancer cells. MMP-14 concentrates in the protrusions of the cells, called lamellipodia in normal cells and invadopodia in cancer cells, to induce a significant increase in cell migration and invasion by degrading components of the ECM and making a path in through the surrounding tissue. In this aspect, MMP-14 should be bound to the plasma membrane in vivo, as membrane-bound MMP-14 has been demonstrated to be more proteolytically active than the soluble recombinant MMP-14. II-) Shedding of cell surface molecules Studies underlying the mechanism of the constitutive shedding of CD44 from the human melanoma cell surface implicated the necessity of MMP-14 with the presence of ADAM-10 for this process. Especially in the hyaluronan based matrix, cleavage of CD44 at the stem region by MMP-14 sheds these molecules from the cell surface and concurrently promotes the migration of the cells from the leading edge. Another cell adhesion molecule, E-cadherin, is also cleaved by MMP-14 to disrupt contact between cells. In the ischemia-induced ARF (acute renal failure), MMP-14 expression is required for the disruption of the cadherin/catenin complex. Syndecan-1 is another cell surface molecule which is cleaved by MMP-14. III-) Cleavage of cytokines and growth factors MMP-14 indirectly plays a major role in cleavage of the cytokines and growth factors by activating pro-MMP-2 and pro-MMP13. It also makes direct contact with several chemokines and growth factors including; the neutrophil chemokine IL-8, secretory leukocyte protease inhibitor, pro-tumor necrosis factor, death receptor-6, and connective tissue growth factor. IV-) Activation of ERK cascade by the cytoplasmic tail of MMP-14 In several studies, overexpression of MMP-14 has been reported to activate the ERK cascade. It is not yet clear how MMP-14 activates ERK signalling, but overexpression of the cytoplasmic-deleted form of MMP-14 has been shown to eradicate ERK activation. Within the cytoplasmic tail, the 573YCQR576 motif has been suggested to be involved in ERK activation. In addition to ERK activation, the role of MMP-14 in the p38 and JNK pathway has also been investigated. V-) Inhibition of MMP-14 function Function of MMP-14 can be abolished either by TIMPs (Tissue Inhibitor of MetalloProteinases) or proteolytic degradation. TIMP-2, -3 and -4 but not TIMP-1 specifically inactivates the functions of MMP-14. Besides TIMPs, RECK and N-Tes can also block the activity of MMP-14 in a similar manner. For the proteolytic cleavage of MMP-14, membrane bound MMP-14 should be internalized by the clathrin-dependent and caveolae-dependent pathways. There is an AP-2 binding site in the cytoplasmic domain of MMP-14, 571LLY573 which is required for the incorporation of MMP-14 into clathrin-coated vesicles. The palmitoylation of the C574 right after the AP-2 binding site has also been demonstrated to be an essential modification for the internalization of MMP-14. |
Homology | All MT-MMPs have shown a 40-50% identity according to their amino acid sequence. In the phylogenetic tree, MMP-14 shares the highest similarity rate with MT2-MMP (MMP-15). |
MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. |
Afzal S, Lalani EN, Poulsom R, Stubbs A, Rowlinson G, Sato H, Seiki M, Stamp GW. |
Hum Pathol. 1998 Feb;29(2):155-65. |
PMID 9490275 |
|
ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. |
Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C, Voelcker V, Sleeman JP, Simon JC. |
J Invest Dermatol. 2009 Jun;129(6):1471-82. Epub 2008 Oct 30. |
PMID 18971959 |
|
Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. |
Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S. |
J Biol Chem. 2008 Mar 7;283(10):6232-40. Epub 2008 Jan 3. |
PMID 18174174 |
|
Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration. |
Cao J, Kozarekar P, Pavlaki M, Chiarelli C, Bahou WF, Zucker S. |
J Biol Chem. 2004 Apr 2;279(14):14129-39. Epub 2004 Jan 16. |
PMID 14729674 |
|
Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. |
Cao J, Rehemtulla A, Pavlaki M, Kozarekar P, Chiarelli C. |
J Biol Chem. 2005 Mar 25;280(12):10974-80. Epub 2005 Jan 6. |
PMID 15637056 |
|
Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. |
Chernov AV, Sounni NE, Remacle AG, Strongin AY. |
J Biol Chem. 2009 May 8;284(19):12727-34. Epub 2009 Mar 13. |
PMID 19286653 |
|
Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). |
Covington MD, Burghardt RC, Parrish AR. |
Am J Physiol Renal Physiol. 2006 Jan;290(1):F43-51. Epub 2005 Aug 2. |
PMID 16077081 |
|
Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340). |
Foda HD, Rollo EE, Drews M, Conner C, Appelt K, Shalinsky DR, Zucker S. |
Am J Respir Cell Mol Biol. 2001 Dec;25(6):717-24. |
PMID 11726397 |
|
Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. |
Gilles C, Polette M, Coraux C, Tournier JM, Meneguzzi G, Munaut C, Volders L, Rousselle P, Birembaut P, Foidart JM. |
J Cell Sci. 2001 Aug;114(Pt 16):2967-76. |
PMID 11686300 |
|
Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). |
Gingras D, Bousquet-Gagnon N, Langlois S, Lachambre MP, Annabi B, Beliveau R. |
FEBS Lett. 2001 Oct 26;507(2):231-6. |
PMID 11684104 |
|
Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. |
Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA. |
J Biol Chem. 1999 Aug 6;274(32):22679-85. |
PMID 10428849 |
|
Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis. |
Hayashi K, Horikoshi S, Osada S, Shofuda K, Shirato I, Tomino Y. |
J Pathol. 2000 Jul;191(3):299-305. |
PMID 10878552 |
|
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. |
Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H. |
Cell. 1999 Oct 1;99(1):81-92. |
PMID 10520996 |
|
Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. |
Itoh Y, Kajita M, Kinoh H, Mori H, Okada A, Seiki M. |
J Biol Chem. 1999 Nov 26;274(48):34260-6. |
PMID 10567400 |
|
Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. |
Jiang A, Lehti K, Wang X, Weiss SJ, Keski-Oja J, Pei D. |
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13693-8. Epub 2001 Nov 6. |
PMID 11698655 |
|
Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. |
Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G. |
J Biol Chem. 1996 Jul 19;271(29):17124-31. |
PMID 8663255 |
|
Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. |
Kojima S, Itoh Y, Matsumoto S, Masuho Y, Seiki M. |
FEBS Lett. 2000 Sep 1;480(2-3):142-6. |
PMID 11034316 |
|
The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. |
Lee MH, Atkinson S, Rapti M, Handsley M, Curry V, Edwards D, Murphy G. |
Cancer Lett. 2010 Apr 1;290(1):114-22. Epub 2009 Oct 7. |
PMID 19815335 |
|
Characterization of the transcriptional regulation of the human MT1-MMP gene and association of risk reduction for focal-segmental glomerulosclerosis with two functional promoter SNPs. |
Munkert A, Helmchen U, Kemper MJ, Bubenheim M, Stahl RA, Harendza S. |
Nephrol Dial Transplant. 2009 Mar;24(3):735-42. Epub 2008 Oct 16. |
PMID 18927121 |
|
Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. |
Overall CM, Dean RA. |
Cancer Metastasis Rev. 2006 Mar;25(1):69-75. (REVIEW) |
PMID 16680573 |
|
Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. |
Pap T, Shigeyama Y, Kuchen S, Fernihough JK, Simmen B, Gay RE, Billingham M, Gay S. |
Arthritis Rheum. 2000 Jun;43(6):1226-32. |
PMID 10857781 |
|
Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. |
Pei D. |
J Biol Chem. 1999 Mar 26;274(13):8925-32. |
PMID 10085137 |
|
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. |
Petrella BL, Lohi J, Brinckerhoff CE. |
Oncogene. 2005 Feb 3;24(6):1043-52. |
PMID 15592504 |
|
Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. |
Poincloux R, Lizarraga F, Chavrier P. |
J Cell Sci. 2009 Sep 1;122(Pt 17):3015-24. (REVIEW) |
PMID 19692588 |
|
Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. |
Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu XP, Jovinge S, Shah PK, Libby P. |
J Biol Chem. 1999 Apr 23;274(17):11924-9. |
PMID 10207013 |
|
Elevated expression of membrane type 1 metalloproteinase (MT1-MMP) in reactive astrocytes following neurodegeneration in mouse central nervous system. |
Rathke-Hartlieb S, Budde P, Ewert S, Schlomann U, Staege MS, Jockusch H, Bartsch JW, Frey J. |
FEBS Lett. 2000 Sep 22;481(3):227-34. |
PMID 11007969 |
|
Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. |
Stamenkovic I, Yu Q. |
J Invest Dermatol. 2009 Jun;129(6):1321-4. |
PMID 19434087 |
|
Structural features of a superfamily of zinc-endopeptidases: the metzincins. |
Stocker W, Bode W. |
Curr Opin Struct Biol. 1995 Jun;5(3):383-90. (REVIEW) |
PMID 7583637 |
|
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. |
Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. |
J Biol Chem. 1995 Mar 10;270(10):5331-8. |
PMID 7890645 |
|
Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. |
Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM. |
Proc Natl Acad Sci U S A. 2004 May 4;101(18):6917-22. Epub 2004 Apr 26. |
PMID 15118097 |
|
Granulocyte-macrophage colony-stimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells. |
Tomita T, Fujii M, Tokumaru Y, Imanishi Y, Kanke M, Yamashita T, Ishiguro R, Kanzaki J, Kameyama K, Otani Y. |
Cancer Lett. 2000 Aug 1;156(1):83-91. |
PMID 10840163 |
|
Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. |
Velasco G, Cal S, Merlos-Suarez A, Ferrando AA, Alvarez S, Nakano A, Arribas J, Lopez-Otin C. |
Cancer Res. 2000 Feb 15;60(4):877-82. |
PMID 10706098 |
|
cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. |
Will H, Hinzmann B. |
Eur J Biochem. 1995 Aug 1;231(3):602-8. |
PMID 7649159 |
|
Transcription factor Sp1 phosphorylation induced by shear stress inhibits membrane type 1-matrix metalloproteinase expression in endothelium. |
Yun S, Dardik A, Haga M, Yamashita A, Yamaguchi S, Koh Y, Madri JA, Sumpio BE. |
J Biol Chem. 2002 Sep 20;277(38):34808-14. Epub 2002 Jul 1. |
PMID 12093818 |
|
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. |
Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, Wang J, Cao Y, Tryggvason K. |
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7. |
PMID 10737763 |
|
Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. |
Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J. |
Int J Cancer. 1998 Mar 2;75(5):780-6. |
PMID 9495249 |
|